Pfizer will request that a booster dose be authorized for children aged 5 to 11 years

The pharmaceutical company Pfizer and its partner BioNTech announced this Thursday that they will soon request that a booster dose of their vaccine against COVID-19 be authorized for children aged 5 to 11 years, after a study has shown that it significantly increases antibodies against the omicron variant.

The clinical trial analyzed data from 140 children who received this third dose approximately six months after the second and documented that antibodies against omicron were 36-fold higher in these cases.

According to the companies, the vaccine was well tolerated and raised no new safety issues. In total, more than 10,000 children under the age of 12 have so far participated in studies of this vaccine.

It’s a statement, Pfizer and BioNTech announced that they plan to apply “in the next few days” for emergency authorization of this booster dose for children between 5 and 11 years of age in the United States.

In addition, they said that they will share data as soon as possible with the European Medicines Agency (EMA) and with regulators from other countries.

Both the US and European regulators have already approved booster doses of the Pfizer both for adults and the age group of 12 to 17 years.